Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.

American journal of clinical pathology - 13 Oct 2020

Rutherford-Parker Nicola J, Campbell Sean T, Colby Jennifer M, Shajani-Yi Zahra

Abstract excerpt

OBJECTIVES: Voxelotor was recently approved for use in the United States as a treatment for sickle cell disease (SCD) and has been shown to interfere with the quantitation of hemoglobin (Hb) S percentage. This study aimed to determine the effect of voxelotor on the quantitation of hemoglobin variant levels in patients with multiple SCD genotypes. METHODS: In vitro experiments were performed to assess the impact...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Benzaldehydes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Hemoglobin, Sickle

Share to Hemoglobins

Share to Hemoglobins, Abnormal

Share to Pyrazines

Share to Pyrazoles

Source

Identifiers

PMID: 32561909
DOI: 10.1093/ajcp/aqaa067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.PMID 32561909Read ↗

Methemoglobin aggregation is modulated by the anti-sickling drug voxelotorSemantic proximity Read ↗

Rapid withdrawal of Voxelotor can precipitate sickle cell disease related crisisSemantic proximity Read ↗

In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell DiseaseSemantic proximity Read ↗

Osivelotor for the treatment of sickle cell diseaseSemantic proximity Read ↗

Assessing the Clinical Outcomes of Voxelotor Treatment in Patients with Sickle Cell DiseaseSemantic proximity Read ↗

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditionsSemantic proximity Read ↗

Hydroxyurea for Children and Adults with Hemoglobin SC DiseaseSemantic proximity Read ↗

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.Semantic proximity Read ↗

Density-based separation in multiphase systems provides a simple method to identify sickle cell disease.Semantic proximity Read ↗

Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin.Semantic proximity Read ↗

Multispectral Imaging for MicroChip Electrophoresis Enables Point-of-Care Newborn Hemoglobin Variant ScreeningSemantic proximity Read ↗

Hemoglobin variant analysis of whole blood and dried blood spots by MS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.